Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Room 2A061, 2/F, Main Clinical Block and Trauma Centre, 30-32 Ngan Shing Street, Shatin, New Territories, Hong Kong SAR; Vascular and Interventional Radiology Foundation Clinical Science Center, Prince of Wales Hospital, The Chinese University of Hong Kong, Room 2A061, 2/F, Main Clinical Block and Trauma Centre, 30-32 Ngan Shing Street, Shatin, New Territories, Hong Kong SAR.
Department of Imaging and Interventional Radiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Room 2A061, 2/F, Main Clinical Block and Trauma Centre, 30-32 Ngan Shing Street, Shatin, New Territories, Hong Kong SAR; Vascular and Interventional Radiology Foundation Clinical Science Center, Prince of Wales Hospital, The Chinese University of Hong Kong, Room 2A061, 2/F, Main Clinical Block and Trauma Centre, 30-32 Ngan Shing Street, Shatin, New Territories, Hong Kong SAR.
J Vasc Interv Radiol. 2019 Nov;30(11):1807-1816. doi: 10.1016/j.jvir.2019.07.035. Epub 2019 Oct 3.
To evaluate the presence of intravesical prostatic protrusion (IPP) and its thickness-to-height (T/H) ratio as a predictor for the clinical outcome and morbidity of prostatic artery embolization (PAE) for benign prostatic hyperplasia.
This was a prospective, single-center, institutional review board-approved study from June 2015 to December 2018 of 82 consecutive patients (age, 53-79 years; median, 66 years) with International Prostate Symptom Score (IPSS) ≥15 and quality-of-life (QOL) score ≥3. The presence of IPP and its T/H ratio were assessed on baseline magnetic resonance imaging for their correlation with the clinical outcomes of suboptimal IPSS (IPSS ≥10) and suboptimal QOL (QOL ≥3) up to 12 months after PAE and the occurrence of post-procedure complications (≤30 days), which caused a certain degree of urinary outflow obstruction. The chi-squared test was used for analysis.
IPP was present in 57 of 82 patients (69.5%). The presence of IPP correlated with the occurrence of post-procedure complications (P = .009) but not with suboptimal IPSS at 12 months (P = .758). IPP with a T/H ratio ≤1.3 correlated with suboptimal IPSS at 12 months (P = .025) and suboptimal QOL at 6 months (P = .025) and 12 months (P = .008), as well as with the occurrence of post-procedure complications (P = .009).
IPP with a T/H ratio ≤1.3 predicted the occurrence of post-procedure complications with urinary obstruction. A T/H ratio ≤1.3 but not the presence of IPP alone predicted the clinical outcome up to 12 months after PAE.
评估膀胱内前列腺突入(IPP)及其厚度与高度比(T/H)作为前列腺动脉栓塞(PAE)治疗良性前列腺增生的临床疗效和发病率的预测因子。
这是一项前瞻性、单中心、机构审查委员会批准的研究,于 2015 年 6 月至 2018 年 12 月期间连续入组 82 例患者(年龄 53-79 岁,中位数 66 岁),这些患者的国际前列腺症状评分(IPSS)≥15 分,生活质量评分(QOL)≥3 分。在基线磁共振成像上评估 IPP 的存在及其 T/H 比值,以评估其与 PAE 后 12 个月内亚优 IPSS(IPSS≥10)和亚优 QOL(QOL≥3)的临床结果以及术后并发症(≤30 天)的相关性,这些并发症导致一定程度的尿流梗阻。采用卡方检验进行分析。
82 例患者中有 57 例(69.5%)存在 IPP。IPP 的存在与术后并发症的发生相关(P=0.009),但与 12 个月时的亚优 IPSS无关(P=0.758)。IPP 的 T/H 比值≤1.3 与 12 个月时的亚优 IPSS(P=0.025)、6 个月和 12 个月时的亚优 QOL(P=0.025 和 P=0.008)以及术后并发症的发生(P=0.009)相关。
IPP 的 T/H 比值≤1.3 预测了伴有尿路梗阻的术后并发症的发生。T/H 比值≤1.3 而不是单纯的 IPP 存在预测了 PAE 后 12 个月的临床结果。